Publication
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.
Authors not recorded
Science2005PMID 16254181stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (3)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 3
- cancerProstate Carcinomacivic_curation1.00
- geneERGcivic_curation1.00
- variantERG Fusioncivic_curation1.00
Curated evidence
Evidence citing this paper (2)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 16254181
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ETV1 Fusion1 | ||||||||
| (diagnostic) | Malignant Prostate Neoplasm | Diagnostic | C | Supports Positive | 4 | submitted | EID7644TMPRSS2-ETV1 fusions are recurrent in prostate cancers. PMID 16254181 · Tomlins et al., 2005 · Open in CIViC | civic |
| ERG Fusion1 | ||||||||
| (diagnostic) | Prostate Carcinoma | Diagnostic | B | Supports Positive | 3 | accepted | EID476TMPRSS2/ERG gene fusion was observed in 23 of 29 (79%) of prostate carcinoma samples, and 90% of ERG expression positive prostate carcinoma samples. PMID 16254181 · Tomlins et al., 2005 · Open in CIViC | civic |